Home › Funds › FARALLON CAPITAL MANAGEMENT, L.L.C. › AGIO

FARALLON CAPITAL MANAGEMENT, L.L.C. position in AGIO

AGIOS PHARMACEUTICALS INC · Health Care

FARALLON CAPITAL MANAGEMENT, L.L.C. reported holding 5,917,400 shares of AGIO (AGIOS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$219.6M, representing 1.02% of its reported portfolio and ranking #27 among its reported holdings. FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed AGIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)5.92M sh
Reported value held$219.59M
Portfolio Weight1.02%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How FARALLON CAPITAL MANAGEMENT, L.L.C.'s AGIO position evolved

FARALLON CAPITAL MANAGEMENT, L.L.C. first disclosed a stake in AGIO in Q3 2023 at 2,750,829 shares (US$68.1M). The position peaked in Q3 2024 at 5,660,866 shares, worth US$251.5M. Across 12 filings, FARALLON CAPITAL MANAGEMENT, L.L.C. increased the stake 6 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q2 2026) shows 5,917,400 shares valued at US$219.6M — an increase of 233,400 shares quarter over quarter.. Notable position changes include a 52% increase in Q4 2023 (shares rose 31% over the following quarter), a 34% increase in Q1 2024 (shares rose 47% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 2.75M $68.08M New
Q4 2023 4.17M $92.81M Add
Q1 2024 5.59M $163.47M Add
Q2 2024 5.65M $243.82M Add
Q3 2024 5.66M $251.51M Hold
Q4 2024 5.67M $186.46M Hold
Q1 2025 5.70M $167.02M Hold
Q2 2025 5.77M $191.83M Add
Q3 2025 5.78M $232.05M Hold
Q4 2025 5.16M $140.44M Reduce
Q1 2026 5.68M $192.29M Add
Q2 2026 5.92M $219.59M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AGIO and 13F data

AGIO (AGIOS PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in AGIO — the largest reported positions include Farallon Capital Management (US$219.6M), Lynx1 Capital Management LP (US$126.5M), ARMISTICE CAPITAL, LLC (US$89.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AGIO

All AGIO fund holders →

FAQ

How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held AGIO?

FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed AGIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in AGIO?

As of Q2 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 5.92M shares of AGIO (AGIOS PHARMACEUTICALS INC), valued at $219.59M, representing 1.02% of its reported portfolio and ranking #27.

Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling AGIO?

In the latest 13F filing (Q2 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. increased its position in AGIO. The position peaked in Q3 2024 at 5.66M shares.

Which other funds hold AGIO?

Other major institutional holders of AGIO include Farallon Capital Management, Lynx1 Capital Management LP, ARMISTICE CAPITAL, LLC, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.